Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Desonide
Therapeutic Area : Dermatology
Study Phase : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Alembic Pharmaceuticals Receives USFDA Final Approval for Desonide Cream, 0.05%
Details : Desonide Cream, 0.05% is a low potency corticosteroid indicated for the relief of inflammatory and Pruritic manifestations of corticosteroid-responsive dermatoses.
Product Name : Desonide-Generic
Product Type : Steroid
Upfront Cash : Inapplicable
September 12, 2022
Lead Product(s) : Desonide
Therapeutic Area : Dermatology
Highest Development Status : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable